Sagimet Biosciences Inc.
Sagimet Biosciences is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors, led by its product candidate denifanstat.
Last updated September 16, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Sagimet Biosciences is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in conditions resulting from the overproduction of the fatty acid palmitate. FASN is described as a regulator of lipid synthesis and a key pathway implicated in multiple diseases such as acne, metabolic dysfunction-associated steatohepatitis (MASH), and certain FASN-dependent tumor types. Its lead product candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor. The company's name is derived from a combination of Sagitta and metabolism.
History
Sagimet Biosciences is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in conditions resulting from the overproduction of the fatty acid palmitate. The company states that its name is derived from a combination of Sagitta and metabolism. David Happel joined Sagimet as chief executive officer in October 2022, and Andreas Grauer, MD, joined Sagimet in April 2026 as Chief Medical Officer. According to the company, Sagimet received IND clearance and an FDA "Study May Proceed" letter in July 2026 and plans to advance denifanstat into a registrational Phase 3 trial in moderate to severe acne patients in 2H 2026.
Products and positioning
Clinical-stage biopharmaceutical company developing novel FASN inhibitors targeting dysfunctional metabolic and fibrotic pathways.
Denifanstat (ASC40)
Lead product candidate; an oral, once-daily pill and selective FASN inhibitor with a differentiated method of action with the potential to target multiple underserved diseases.
TVB-3567
Listed in the development pipeline as a topical FASN inhibitor (FASNi Topical) for dermatology.
Recent events
Sagimet appoints Elizabeth Grammer to its board[6]
Reported:
Sagimet Biosciences announced the appointment of Elizabeth Grammer to its board of directors.
Sources6 sources
Cite this profile: Cite the canonical profile. /brand-wiki/sagimet-biosciences-inc-united-states · Editorial policy · How profiles are compiled